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The Epstein-Barr virus latent membrane protein 1 (LMP1) oncoprotein causes multiple cellular changes,
including induction of epidermal growth factor receptor (EGFR) expression and activation of the NF-kB
transcription factor. LMP1 and the cellular protein CD40, which also induces EGFR expression, interact with
the tumor necrosis factor receptor-associated factor (TRAF) proteins. The LMP1 carboxy-terminal activation
region 1 signaling domain interacts specifically with the TRAFs and is essential for EGFR induction through
a mechanism independent of NF-kB alone. LMP1 and CD40 share a common TRAF binding motif, PXQXT.
In this study, the PXQXT motifs in both LMP1 and CD40 were altered and mutant proteins were analyzed for
induction of EGFR expression. Replacement of the T residue with A in CD40 completely blocked induction of
the EGFR, while the same mutation in LMP1 did not affect EGFR induction. Replacement of both P and Q
residues with A’s in LMP1 reduced EGFR induction by >75%, while deletion of PXQXT blocked EGFR
induction. These results genetically link EGFR induction by LMP1 to the TRAF signaling pathway. Overex-
pression of TRAF2 potently activates NF-kB, although TRAF2 did not induce expression of the EGFR either
alone or in combination with TRAF1 and TRAF3. In vivo analyses of the interaction of the TRAFs with LMP1
variants mutated in the PXQXT domain indicate that high-level induction of EGFR expression requires
interaction with TRAF1, -2, and -3. However, exogenous expression of TRAF3 decreased EGFR induction
mediated by either LMP1 or CD40. These data suggest that TRAF-mediated activation of EGFR expression
requires assembly of a complex containing the appropriate stoichiometry of TRAF proteins clustered at the cell
membrane with LMP1.
The Epstein-Barr virus (EBV)-encoded latent membrane
protein 1 (LMP1) is essential for immortalization of B lym-
phocytes infected in vitro with EBV and is expressed in lym-
phomas which develop in immunocompromised individuals
(32, 47, 66). LMP1 is also expressed in all cases of premalig-
nant lesions related to the human malignancy nasopharyngeal
carcinoma (NPC) and in a majority of NPC biopsies (12, 46,
67). LMP1 is the only EBV protein shown to have transform-
ing properties in rodent fibroblasts, highlighting the impor-
tance of this viral oncoprotein in cellular transformation asso-
ciated with EBV infection (1, 43, 60). The function of LMP1
and the involvement of LMP1 in the activation of cellular
signal transduction pathways are just beginning to be under-
stood. Expression of LMP1 in B lymphocytes induces the tran-
scription of many genes, including those encoding activation
antigens such as CD23 and CD40, adhesion molecules such as
ICAM-1, LFA-1, and LFA-3, and molecules which inhibit pro-
grammed cell death such as Bcl-2, Mch-1, and A20 (16, 22, 33,
35, 36, 62–64). Expression of LMP1 in epithelial cells induces
expression of the genes encoding the epidermal growth factor
receptor (EGFR) and the A20 molecule (38–40). Induction of
these genes is likely to play an important role in the transfor-
mation of epithelial cells by LMP1. LMP1 activates the NF-kB
transcription factor and also activates the N-terminal Jun ki-
nase (JNK1) (19, 21, 25, 34, 42, 45). Activation of these path-
ways is likely to mediate some but not all of the LMP1-induced
changes in gene expression described above.
LMP1 consists of a 24-amino-acid cytoplasmic domain lo-
cated at the amino terminus, a membrane-spanning hydropho-
bic domain consisting of six transmembrane domains con-
nected by short turns between amino acids 25 and 187,
followed by a 200-amino-acid cytoplasmic domain at the car-
boxy terminus (Fig. 1) (13, 23). The six transmembrane do-
mains of LMP1 are essential for the activation of signaling
pathways, indicating that proper aggregation in the plasma
membrane is required for LMP1 function (25, 37, 40). Muta-
tional analysis of LMP1 with respect to activation of cellular
signaling pathways further divides the carboxy-terminal do-
main into three regions. Carboxy-terminal activation region 1
(CTAR1), located between amino acids 187 and 231, is essen-
tial for EGFR induction and is a relatively weak activator of
NF-kB (25, 40, 42). CTAR2, located between amino acids 352
and 386, is responsible for activation of JNK and is the major
NF-kB activation domain (6, 25, 34, 40, 42). The amino acids
separating these two domains (amino acids 232 to 351) are not
associated with any known function.
LMP1 has many similarities to the tumor necrosis factor
receptor (TNFR) superfamily. The TNFR superfamily com-
prises a large group of transmembrane proteins including
CD40 and CD30 that transmit extracellular signals but do not
contain the intrinsic tyrosine kinase activity often associated
with membrane receptors (56, 58, 59). Instead, the TNFR
family members initiate signaling events through interaction of
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their cytoplasmic domains with the recently identified tumor
necrosis factor receptor-associated factors (TRAFs) (8, 44, 48,
49, 53). The mechanisms by which the TRAFs activate signal-
ing cascades are just beginning to be understood.
Several lines of evidence indicate that LMP1 functions as a
constitutively activated member of the TNFR superfamily.
First, expression of LMP1 in B-lymphoid cells induces many of
the phenotypic changes characteristic of EBV immortalization
(4, 5, 11, 17, 52). Activation of CD40, in conjunction with
interleukin-4 stimulation, can mimic EBV-induced immortal-
ization of human lymphocytes in short-term culture, suggesting
parallel roles for CD40 and LMP1 in signal transduction path-
ways (4, 17, 50). CD40, like LMP1, can induce expression of
the EGFR in epithelial cells, which also indicates a similarity
between LMP1 and CD40 signaling (40). Second, signaling
from CTAR1 involves the TRAF signaling pathway, and LMP1
interacts with TRAF1, -2, -3, and -5 (6, 10, 44, 51). The precise
TRAF interaction motif in CTAR1 has been identified by
homology with the TNFR family members CD40 and CD30 (7,
18, 24). The TRAFs bind to the PXQXT motif located be-
tween amino acids 204 and 208 of LMP1 (10, 15, 51). TRAF2
appears to be a positive regulator of TRAF-mediated NF-kB
activation; in support of this finding, NF-kB activation by
CTAR1 in LMP1 involves interactions with TRAF1 and
TRAF2 (10, 31). In contrast, TRAF3 appears to be a negative
regulator of the TRAF pathway, and accordingly, overexpres-
sion of TRAF3 blocks NF-kB activation from CTAR1 but not
CTAR2 (10, 11, 40, 48). The mechanism of NF-kB activation
by CTAR2 may involve interaction with the TNFR-associated
death domain protein (TRADD) and studies have localized
CTAR2 to amino acids 379 to 384 (14, 29). Although the
interaction with TRADD may activate NF-kB through the
interaction with TRAF2, the details of CTAR2 signaling re-
main unknown (10, 29, 31).
Recent experiments indicate that the CTAR1 domain in
LMP1 is essential for induction of EGFR expression (40). This
induction of EGFR expression by LMP1 occurred at the RNA
level, indicating that LMP1 either activates the EGFR pro-
moter or stabilizes the EGFR mRNA (39, 40). Expression of
an LMP1 mutant deleted for CTAR2, LMP1(1-231), induced
high levels of EGFR expression. In contrast, an LMP1 mutant
deleted for CTAR1, LMP1(D187-351), activated NF-kB to
high levels in both transient and stable assays but was com-
pletely defective for EGFR induction (40). These results indi-
cate that NF-kB activation alone is unable to induce EGFR
expression. However, since the CTAR1 signaling domain is
linked to both EGFR induction and NF-kB activation, the
contribution of NF-kB to the induction of EGFR expression
could not be determined.
The experiments presented in this study were designed to
determine the contribution of NF-kB activation from CTAR1
to the induction of EGFR expression, to analyze the roles of
the TRAF proteins in these signaling pathways, and to identify
residues in the PXQXT motif in CTAR1 which are responsible
for EGFR induction and interaction with the TRAFs.
MATERIALS AND METHODS
Cell lines and establishment of derivatives. C33A epithelial cells, derived from
a human cervical carcinoma (human papillomavirus negative), were grown at
37°C in Dulbecco’s modified Eagle’s medium (DMEM-H) supplemented with
10% fetal bovine serum (Gibco-BRL) and antibiotics. Cells were routinely grown
in 150-mm-diameter cell culture dishes and subcultured three times weekly.
C33A cell lines expressing CD40, wild-type LMP1 [LMP1(WT)], and mutants of
LMP1 were obtained by selection in 600 mg of G418 (Geneticin; Gibco-BRL)
following transfection with an expression construct containing the appropriate
gene. Briefly, 5 3 105 cells were seeded in 60-mm-diameter tissue culture dishes
and Lipofectin transfected as specified by the manufacturer (Gibco-BRL) with 5
mg of DNA. Cells were fed with fresh medium 24 h posttransfection, and 48 h
posttransfection, the medium was replaced with fresh medium containing G418.
Cell lines were created by pooling .50 G418-resistant colonies.
Plasmids and expression vectors. The expression vector used for most of the
constructs in this study is pcDNA3 (Invitrogen), which contains the cytomega-
lovirus (CMV) immediate-early promoter, polyadenylation sequence from the
bovine growth hormone gene, and neomycin resistance cassette. The LMP1
cDNA was subcloned into the EcoRI site of pcDNA3. The construction of
pcDNA3 vectors expressing FLAG-tagged LMP1 and LMP1 mutants has been
described previously (40). The CD40 cDNA was subcloned into the HindIII and
XhoI sites of pcDNA3. pSG5- and pcDNA3-based expression vectors for
TRAF1, TRAF2, and TRAF3 were kindly provided by Elliott Kieff. The pSG5
vector contains the simian virus early promoter and intron sequences from the
rabbit b-globin gene (Stratagene). TRAF3 was also subcloned into the pMEP4
expression vector (Invitrogen). The pMEP4 vector contains the human metallo-
thionein promoter, herpes simplex virus thymidine kinase polyadenylation se-
quence, and hygromycin resistance cassette. pMEP4 and pMEP4-TRAF3 were
transfected into C33A cells as described above and selected 48 h following
transfection in medium containing 100 mg of hygromycin (Boehringer Mann-
heim) per ml. To coexpress TRAF3 with either LMP1 or CD40, pcDNA3-based
vectors for LMP1 or CD40 were transfected into the pMEP4-TRAF3 cell line
and selected in G418. Transfection of a fivefold excess of pSG5-TRAF1 with
pcDNA3-TRAF2 in the pMEP4-TRAF3 cell lines, followed by selection in
G418, created a cell line overexpressing all three TRAFs. The CMV-IkBa(S32/
36A) expression vector, which encodes an IkBa molecule in which serines 32 and
36 have been replaced by alanines, was a kind gift of Dean Ballard (55). Cell lines
expressing IkBa(S32/36A) were created by transfecting a fivefold excess of
CMV-IkBa(S32/36A) with pcDNA3-based plasmids and selected in G418.
Construction of TRAF interaction domain LMP1 and CD40 mutants. The
LMP1 cDNA was subcloned into the EcoRI site of the pGEM3Z vector to
facilitate construction of LMP1 mutants. PCR using Vent polymerase (New
England Biolabs) was used to produce all mutant sequences. For the LMP1
mutants, following PCR amplification, the PCR products were digested with
BsaBI and MscI and ligated into pGEM3Z-LMP1 which was digested with the
same enzymes (except for EGRHH221-225AGAAA, which was digested with
BsaBI and NaeI). The nucleotides representing the mutated codons are bold-
faced in the sequences below. The sense oligonucleotide used in the PCR was
59-AACAAAACTGGTGGACTCTATTGGTTGATCTCCTTTGGC-39. For the
P204A mutant, the antisense oligonucleotide was 59-ATTCATGGCCAGAATC
ATCGGTAGCTTGTTGAGCGTGCG-39. For the PQ204/206AA mutant, the
antisense oligonucleotide was 59-ATTCATGGCCAGAATCATCGGTAGCTG
CTTGAGCGTGCG-39. For the T208A mutant, the antisense oligonucleotide
was 59-ATTCATGGCCAGAATCATCGGCAGCTTGTTGAGGGTGCG-39.
For the DD209/210AA mutant, the antisense oligonucleotide was 59-ATTCAT
GGCCAGAAGCAGCGGTAGCTTGTTGAGGGGCCG-39. For the D204-208
mutant, the antisense oligonucleotide was 59-TTCATGGCCAGAATCATCGT
GCGGGAGGGAGTCATC-39). For the 204-208AAAAA mutant, the antisense
oligonucleotide was 59-ATTCATGGCCAGAATCATCGGCAGCTGCTGCAGC
FIG. 1. Model depicting the molecular structures and locations of functional
domains in LMP1. LMP1 contains a 24-amino-acid cytoplasmic amino terminus,
a transmembrane hydrophobic domain, and a 200-amino-acid cytoplasmic car-
boxy terminus. The carboxy terminus contains the major signaling domains in
LMP1. CTAR1 mediates interaction with the TRAFs, induces EGFR expres-
sion, and is the minor NF-kB-activating region; CTAR2 is the major NF-kB-
activating region. The location of the TRAF-interacting motif, PXQXT, is also
indicated.
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GTGCG-39. For the EGRH221-225AGAAA mutant, the antisense oligonucle-
otide was 59-GTCGCCGGCTCCACTCACGAGCAGGGCGGCTGCGCCCGC
GTTGGA-39. The mutated LMP1 cDNAs were then subcloned into the EcoRI
sites of pcDNA3. To construct FLAG-LMP1(WT) expression constructs con-
taining these point mutants, the SfiI-BstEII fragments from the full-length con-
structs was subcloned into FLAG-LMP1(WT) cut with the same enzymes. To
construct FLAG-LMP1(1-231) expression constructs containing the point muta-
tions, the SfiI-MscI fragment from the full-length constructs was subcloned into
the same sites in FLAG-LMP1(1-231).
The T234A mutant of CD40 was constructed in the same way except that the
mutant PCR products were digested with BamHI and BstEII and subcloned into
pcDNA3-CD40 digested with the same enzymes. The sense oligonucleotide was
59-TCTGTGGTCCCCAGGATCCGGCTGAGAGCCCTGGTGGTGA-39; the
antisense oligonucleotide was 59-CTCCTGGGTGACCGGTTGGCATCCATG
TAAAGCTTCCTGCAC-39. All mutations were confirmed by DNA sequencing
using a model 377 DNA sequencer (Perkin-Elmer, Applied Biosystems Division)
at the UNC-CH Automated DNA Sequencing Facility.
Immunoprecipitations. C33A cells were transfected in duplicate with each of
the mutated FLAG-LMP1 molecules (full length). Briefly, 1.5 3 106 cells were
seeded in 100-mm-diameter tissue culture dishes and 24 h later cells were
Lipofectin treated as specified by the manufacturer with 15 mg of each plasmid.
Six plates were transfected with each of the LMP1 mutants; 24 h after lipofec-
tion, DMEM-H containing 10% fetal bovine serum was added, and 48 h after
lipofection, cells were harvested. Whole-cell extracts were prepared by washing
cells once in cold phosphate-buffered saline and then lysing cells in 900 ml of lysis
buffer (20 mM HEPES, 0.5% Nonidet P-40 [NP-40], 250 mM NaCl, 10% glyc-
erol, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride [PMSF], 2.5 mg of
aprotinin per ml, 25 mg of leupeptin per ml) for 20 min at 4°C. The supernatant
was clarified by centrifugation and was stored at 280°C until use. FLAG-LMP1
and associated proteins were immunopurified with 100 ml of anti-FLAG M2
affinity gel (Sigma) for .3 h with constant rocking at 4°C. Immunocomplexes
were washed three times in lysis buffer, diluted in 23 sample buffer, boiled for 5
min, and electrophoresed on sodium dodecyl sulfate (SDS)–10% polyacrylamide
gels. Bound LMP1 and TRAF proteins were detected by immunoblotting as
described below. For experiments with overexpression of TRAF1 or TRAF3, 5 3
105 cells were seeded in 60-mm-diameter tissue culture dishes and 24 h later were
subjected to lipofection in duplicate with 2.5 mg of LMP1 construct and 2.5 mg
of either TRAF1 or TRAF3 construct. For experiments with TRAF2 overex-
pression, 1.5 3 106 cells were seeded in 100-mm-diameter tissue culture dishes
and transfected with 7.5 mg of mutant LMP1 constructs and 7.5 mg of TRAF2.
Duplicate plates were combined, and whole-cell extracts were prepared by lysing
cells in 250 ml of lysis buffer. FLAG-LMP1 and associated proteins were immu-
nopurified with 25 ml of anti-FLAG M2 affinity gel. Bound LMP1 and TRAF
proteins were detected by immunoblotting as described below.
Nuclear and cytoplasmic extracts. Cell lines expressing various derivatives of
LMP1 were seeded in 100-mm-diameter dishes and were harvested for extract
preparation when the cells were ;75% confluent. Extracts were prepared by a
method described previously (9, 38). Briefly, cells were washed once with ice-cold
phosphate-buffered saline, scraped from the dishes, collected in microcentrifuge
tubes, and lysed for 3 min on ice in 5 pellet volumes of cytoplasmic extraction
buffer (10 mM HEPES [pH 7.6], 60 mM KCl, 1 mM EDTA, 0.1% NP-40, 1 mM
dithiothreitol, 1 mM PMSF, 2.5 mg each of aprotinin, leupeptin, and pepstatin
per ml). Nuclei were collected (1,500 rpm, 4°C, 5 min), and the supernatants
containing the cytoplasmic fraction were transferred to fresh tubes. Nuclei were
washed with 300 ml of cytoplasmic extraction buffer without NP-40, collected as
before, and lysed in 3 pellet volumes of nuclear extraction buffer (20 mM Tris
[pH 8.0], 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM PMSF, 25%
glycerol, 2.5 mg each of aprotinin, leupeptin, and pepstatin per ml). The final salt
concentration was adjusted to ;400 mM with NaCl, and nuclear pellets were
vortexed and incubated on ice for 10 min. Cytoplasmic and nuclear extracts were
cleared (14,000 rpm, 4°C, 10 min) and transferred to fresh tubes. Glycerol was
added to the cytoplasmic extracts to a final concentration of 20%, and protein
concentrations were determined with the Bio-Rad protein assay dye reagent.
Immunoblot analysis. Cytoplasmic or whole-cell extracts (100 mg) were solu-
bilized in 23 sample buffer, boiled for 10 min, separated on SDS–8 or 10%
polyacrylamide gels, and transferred to supported nitrocellulose filters (Schlei-
cher & Schuell), using a Bio-Rad Trans-blot wet electrophoretic transfer appa-
ratus. Filters were stained with Ponceau S stain to visualize equal loading of
protein in all lanes. Nonspecific reactivity was blocked by incubation overnight in
Tris-buffered saline containing 0.1% Tween 20 and 5% nonfat dried milk
(BLOTTO). Supernatant from the S12 monoclonal antibody (generous gift of
David A. Thorley-Lawson) was used at a 1:10 dilution in BLOTTO for the
detection of LMP1. A rabbit antiserum raised against the carboxy-terminal 100
amino acids of the EGFR fused to glutathione S-transferase (GST) (ERCT) was
used at a 1:1,500 dilution in BLOTTO for the detection of the EGFR (kind gift
of H. Shelton Earp). Rabbit antisera directed against TRAF1 (S-19), TRAF2
(C-20), TRAF3 (C-20), and CD40 (C-20) were used at a 1:200 dilution as
specified by the manufacturer (Santa Cruz Biotechnology, Inc.). Antiserum di-
rected against the A20 protein (generous gift of Vishva Dixit) was used at 1:500.
Antiserum directed against IkBa (Rockland) was used at 1:2,000. Appropriate
secondary anti-mouse or anti-rabbit antibodies (Amersham) were used at a
dilution of 1:2,000 in BLOTTO to detect bound primary antibody. Reactive
proteins were detected by incubation of washed filters (TBST) in the Amersham
enhanced chemiluminescence system followed by exposure to autoradiographic
film.
Electrophoretic mobility shift assays (EMSAs). Nuclear extracts (10 mg) were
incubated for 15 min at room temperature with a 32P-labeled probe containing
a kB site from the class I major histocompatibility complex promoter (59-CAG
GGCTGGGGATTCCCCATCTCCACAGTTTCACTTC-39) in binding buffer
(10 mM Tris [pH 7.7], 50 mM NaCl, 0.5 mM EDTA, 1 mM dithiothreitol, 10%
glycerol) with 2 mg of poly(dI-dC) z poly(dI-dC) (Pharmacia Biotech) (2, 3, 20,
54). Complexes were separated on 5% polyacrylamide gels in high-ionic-strength
Tris-glycine-EDTA buffer (25 mM Tris, 190 mM glycine, 1 mM EDTA), dried,
and subjected to autoradiography. For supershift experiments, 1- to 5-ml aliquots
of rabbit polyclonal antibodies against the NF-kB subunits p50 (sc-114; Santa
Cruz Biotechnology), p52 (catalog no. 100-4185; Rockland), and p65 (catalog no.
100-4165; Rockland) were incubated with nuclear extracts for 15 min prior to the
addition of poly(dI-dC) z poly(dI-dC) and 32P-labeled probe. Complexes were
then analyzed as described above.
RESULTS
LMP1 signaling domains induce different NF-kB com-
plexes. Previous analysis of the function of LMP1 mutants has
indicated that two different signaling domains can activate the
NF-kB transcription factor (Fig. 1) (6, 10, 25, 31, 40, 42).
However, only the TRAF signaling domain, CTAR1, can in-
duce expression of the EGFR. This finding suggested that a
specific component of the TRAF signaling pathway that is not
activated by CTAR2 is essential for the induction of EGFR
expression.
To determine if CTAR1 activated a specific subset of NF-kB
components distinct from CTAR2, the LMP1 mutants de-
scribed in Fig. 2A were stably transfected into C33A epithelial
cells. LMP1(D187-351) lacks the TRAF interaction domain,
CTAR1, but retains the major NF-kB activation domain,
CTAR2. LMP1(129-386) is deleted for the first four trans-
membrane domains and is unable to insert properly into the
cell membrane (37, 61). LMP1(1-187) is deleted for the entire
carboxy-terminal cytoplasmic domain and therefore does not
contain either CTAR1 or CTAR2. LMP1(1-231) retains
CTAR1 but is deleted for CTAR2. Nuclear extracts from
C33A cell lines expressing individual LMP1 mutants were
analyzed by EMSA (Fig. 2B). As expected LMP1(WT),
LMP1(D187-351), and LMP1(1-231) each induced the trans-
location of NF-kB components into the nucleus. The LMP1
FIG. 2. Mutational analysis of LMP1 mutants with respect to NF-kB activa-
tion and EGFR induction. (A) Diagram of LMP1 mutants used in this experi-
ment. The domains of LMP1 retained by the individual mutants are depicted. (B)
EMSA analysis of nuclear NF-kB binding activity in extracts from C33A cells
stably transfected with the indicated LMP1 constructs. The arrows indicate the
specific complexes induced by LMP1. (C) EMSA analysis of NF-kB binding
activity of LMP1 compared to CD40 and TRAF2.
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mutants LMP1(129-386) and LMP1(1-187), which have been
described as unable to activate NF-kB in transient reporter
gene assays, did not induce the translocation of NF-kB com-
ponents into the nucleus. Full-length LMP1(WT) induced
three different NF-kB complexes (complexes 1, 2, and 3). In-
terestingly, while LMP1(1-231) induced the same three NF-kB
complexes, LMP1(D187-351) induced only complex 1 and min-
imal or undetectable levels of complex 3. Immunoblot analyses
of the expression levels of LMP1(1-231) and LMP1(D187-351)
indicated that these mutants were expressed at equal levels
(data not shown) (40). Supershift analyses of these complexes
indicated that complex 3 contains p50-p50 homodimers, com-
plex 2 contains p50-p52 heterodimers, and complex 1 contains
p52 and p65 as well as additional unknown components as
previously described (38, 45). Since CTAR1 and CTAR2 in-
duced different NF-kB complexes, the repertoire of NF-kB
complexes induced by LMP1 was compared to those of CD40
and TRAF2, which activate NF-kB through the TRAF path-
way. EMSA analysis indicated that LMP1, CD40, and TRAF2
all induced three NF-kB complexes in C33A cells (Fig. 2C).
Thus, CTAR1-mediated activation of complexes 1, 2, and 3
parallels the activation of NF-kB mediated by the TRAF sig-
naling pathway. These results further distinguish the unique
nature of CTAR2-mediated activation of NF-kB since this
signaling domain activates complex 1 only.
Inhibition of NF-kB activation with a constitutively active
IkBa reduces EGFR induction by LMP1 and CD40. To deter-
mine if the specific NF-kB complexes induced by CTAR1
contribute to EGFR induction, C33A cell lines which express
LMP1(WT) or CD40 either in the presence or in the absence
of a constitutively active IkBa inhibitor of NF-kB were estab-
lished (55). This IkBa molecule contains serine-to-alanine mu-
tations at amino acids 32 and 36, IkBa(SS32/36AA), and is
unable to be phosphorylated and degraded (55). Extracts from
these cell lines were analyzed by immunoblotting for EGFR
induction (Fig. 3, top). In control cells, LMP1 and CD40 in-
duced high levels of EGFR expression as expected. However,
in the presence of IkBa(SS32/36AA), LMP1- and CD40-me-
diated induction of EGFR expression was reduced by approx-
imately 50 to 70%. IkBa(SS32/36AA) expression in these cell
lines was confirmed by immunoblot analysis (Fig. 3, bottom).
Since the antibody also reacts with endogenous IkBa, low-level
expression of IkBa was also detected and was particularly
evident in the CD40-expressing cell line. These results indicate
that although NF-kB by itself is insufficient to induce EGFR
expression, activation of NF-kB by the TRAF pathway con-
tributes to high levels of EGFR induction.
Activation of NF-kB and induction of EGFR expression by
full-length LMP1 containing mutations in the TRAF binding
domain PXQXT. LMP1 contains a five-amino-acid sequence,
PQQAT, which constitutes the minimal TRAF binding core
(Fig. 4A). LMP1 shares this motif with the other TRAF-inter-
acting proteins, and the consensus sequence is defined as
PXQXT (Fig. 5A). Alanine substitution mutations were made
in this motif and in surrounding residues, and the locations of
residues mutated in the core PXQXT motif are indicated by
asterisks in Fig. 4A. Each of the LMP1 mutant constructs was
transfected into C33A cells, and cell lines expressing individual
LMP1 constructs were established following selection in G418.
FIG. 3. EGFR induction is decreased in the presence of a constitutively
active IkBa. LMP1 or CD40 was transfected into C33A cells in both the absence
and the presence of a constitutively active IkBa(SS32/36AA). The resulting cell
lines were analyzed by immunoblotting for EGFR expression (top) and the
constitutively active IkBa(SS32/36AA) (bottom). Migration of molecular mass
standards (in kilodaltons) is shown. FIG. 4. Effects of mutations in the LMP1 TRAF binding motif PXQXT on
NF-kB activation and EGFR induction. (A) Amino acids 200 to 227 of the
carboxy-terminal domain of LMP1. The TRAF binding PXQXT motif is indi-
cated by a box, and asterisks denote the residues of the core element. Amino
acids 221 to 225 show some similarity with a region in the CD40 TRAF inter-
action domain and are also indicated by a box. The shaded residues indicate
those that were mutated and analyzed in the experiments. (B) EMSA of nuclear
NF-kB binding activity in extracts from C33A cells stably transfected with the
indicated LMP1 constructs. Induced complexes are indicated by arrows. (C)
Immunoblot analysis of EGFR and A20 induction by LMP1 mutants. Migration
of molecular mass standards (in kilodaltons) is shown.
FIG. 5. Effects of mutations in the CD40 TRAF binding motif PXQXT on
EGFR induction. (A) Alignment of the amino acid sequences of several proteins
known to interact with the TRAF molecules reveals a common motif, PXQXT,
which is essential for interaction with the TRAFs. (B) The effect of replacement
of Thr-234 with Ala in the PXQXT motif in CD40 on the induction of EGFR
expression was analyzed by immunoblotting (top). Both wild-type and mutant
CD40 proteins were expressed at equal levels as determined by immunoblotting
(bottom). Migration of molecular mass standards (in kilodaltons) is shown.
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Nuclear extracts from each cell line were analyzed by EMSA
for the presence of TRAF-mediated activation of NF-kB (Fig.
4B). Total disruption of the PXQXT domain, in mutants
LMP1(D204-208) and LMP1(204-208AAAAA), greatly re-
duced induction of complexes 2 and 3. The complexes induced
by these mutants were very similar to those induced by
LMP1(D187-351), indicating that complete disruption of the
TRAF domain in CTAR1 eliminates NF-kB activation from
this domain, leaving only activity due to CTAR2 signaling
(compare Fig. 4B and 2B). Mutation of proline 204 to alanine,
LMP1(P204A), slightly decreased the levels of complexes 2
and 3, while mutation of proline 204 and glutamine 206 to
alanines, LMP1(PQ204/206AA), further decreased the levels
of complexes 2 and 3. These results indicate that increasingly
disruptive mutations of the PXQXT motif (P204A the least
and D204-208 the strongest) reduces the strength of the TRAF
signal which activates NF-kB complexes 2 and 3. Interestingly,
mutation of threonine 208 to alanine, LMP1(T208A), did not
reduce the TRAF-mediated component of NF-kB activation.
This result was somewhat surprising since this position appears
to be conserved in the TRAF-interacting proteins and the
analogous mutation in CD40 abolishes TRAF binding and
NF-kB activation (24, 26–28, 52). Two additional substitution
mutants in CTAR1 which are located outside the PXQXT
motif were also tested for activation of NF-kB. Replacement of
aspartic acid residues 209 and 210 [LMP1(DD209/210AA)] or
of residues between amino acids 221 and 225 [LMP1(221-
225AGAAA)] has been shown to reduce TRAF binding to
GST-LMP1 proteins (10, 51). Mutation of these residues did
not reduce the TRAF-mediated component of NF-kB activa-
tion, indicating that these mutants retain sufficient TRAF in-
teraction to activate NF-kB (Fig. 4B).
These cell lines were also analyzed by immunoblotting for
induction of EGFR expression (Fig. 4C, top). Mutations of
amino acids in the PXQXT motif also reduced the ability
of LMP1 to induce EGFR expression. Specifically the
LMP1(P204A) mutant had slightly reduced EGFR induction,
while the double mutant, LMP1(PQ204/206AA), had greatly
reduced EGFR induction. Interestingly, the LMP1(T208A)
mutant induced levels of EGFR expression comparably to
LMP1(WT). The LMP1(DD209/210) and LMP1(221-
225AGAAA) mutants also induced EGFR expression compa-
rably to LMP1(WT). As would be predicted, the two mutants
with completely mutated PXQXT motifs, LMP1(D204-208)
and LMP1(204-208AAAAA), were incapable of inducing
EGFR expression.
The effect of mutations in the PXQXT motif were also
analyzed in the context of an LMP1 mutant consisting of amino
acids 1 to 231. FLAG-LMP1(1-231) containing either a single
substitution of alanine for proline 204 (P204A) or a double
substitution of alanines for proline 204 and glutamine 206
(PQ204/206AA) was defective for induction of EGFR expres-
sion, while substitution of alanine for threonine 208 (T208A)
did not affect EGFR induction (data not shown). These results
reveal that PXQXT mutations in LMP1(1-231) have a more
severe effect than mutations in the full-length molecule and
indicate that the overall structure of LMP1 contributes to the
signaling capacity of LMP1 as well as the stability of LMP1-
TRAF interactions.
Since all of these LMP1 mutants retain CTAR2, mutations
in the PXQXT motif should disrupt TRAF signaling but
should not completely block activation of NF-kB. Immunoblot
analysis of the expression of the A20 protein, whose expression
is regulated by NF-kB, indicated that CTAR2-mediated acti-
vation of NF-kB complex 1 was sufficient to induce expression
of A20 despite the presence of disruptive mutations in the
CTAR1 PXQXT motif (Fig. 4C, middle). Immunoblot analysis
of LMP1 expression indicated that the mutants were all ex-
pressed at approximately equal levels (Fig. 4C, bottom). Im-
portantly, these results demonstrate that mutations in the
PXQXT motif in CTAR1 can specifically disrupt TRAF-me-
diated NF-kB activation and TRAF-mediated EGFR induc-
tion but do not affect the stability of LMP1 or NF-kB activation
mediated by CTAR2.
Induction of EGFR expression by CD40 is blocked by mu-
tation of the PXQXT motif. Alignment of the TRAF interac-
tion domains of several TRAF binding proteins including
LMP1 and CD40 revealed a homology limited to the PXQXT
motif which does not extend to amino acids surrounding this
core motif (Fig. 5A). Substitution of threonine 234 with ala-
nine (T234A) not only disrupts interaction with TRAF3 but
also prevents CD40-mediated signaling (24, 26, 52). Expres-
sion constructs for wild-type [CD40(WT)] and mutant
[CD40(T234A)] proteins were transfected into C33A cells, and
cell lines were established. Previous studies have indicated that
overexpression of CD40 can activate signaling pathways in the
absence of ligand, which is most likely due to the clustering of
CD40 in the cell membrane (48). Therefore the experiments
with overexpressed CD40 in C33A cells were analyzed in the
absence of ligand. These cell lines were analyzed by immuno-
blot for EGFR expression (Fig. 5B, top) and CD40 expression
(Fig. 5B, bottom). As expected, CD40(WT) was a potent in-
ducer of EGFR expression whereas CD40(T234A) was inca-
pable of inducing EGFR expression. Expression of wild-type
and mutant CD40 proteins was confirmed in both cell lines,
and the two proteins were expressed at similar levels. These
data indicate that the TRAF signaling pathway activated by
CD40 is essential for EGFR induction. Interestingly, while the
T234A mutation in the TRAF binding motif in CD40 com-
pletely blocked EGFR induction (Fig. 5B), the parallel muta-
tion T208A in LMP1 (Fig. 4C) did not block LMP1-mediated
induction of EGFR expression. These results suggest that
while the core PXQXT motif in both of these proteins is
essential for TRAF signaling, other residues surrounding the
motif may contribute to TRAF interaction and activation of
signaling pathways.
Interaction of LMP1 PXQXT mutants with TRAF1, TRAF2,
and TRAF3. The results presented in Fig. 4C reveal that the
PXQXT motif in CTAR1 is essential for LMP1 to induce
expression of the EGFR. To further explore this unique
TRAF-mediated signal, the ability of each of the full-length
LMP1 constructs with point mutations in the TRAF binding
PXQXT motif to interact with TRAF1, TRAF2, and TRAF3
was analyzed. Expression constructs for FLAG-LMP1(WT)
and FLAG-LMP1 containing the point mutations described
above were transfected into C33A cells. Wild-type and mutant
FLAG-LMP1 constructs were immunopurified with anti-
FLAG affinity gel, immunocomplexes were subjected to SDS-
polyacrylamide gel electrophoresis, and bound TRAF proteins
were analyzed by immunoblotting (Fig. 6A). TRAF1 and
TRAF3 strongly interacted with FLAG-LMP1(WT), but an
interaction between FLAG-LMP1(WT) and TRAF2 could not
be detected. Compared to FLAG-LMP1(WT), the interaction
of FLAG-LMP1(P204A) with TRAF3 was slightly weaker,
FLAG-LMP1(PQ204/206AA) interacted very weakly with
TRAF3, and FLAG-LMP1(D204-208) was unable to interact
with TRAF3. Interestingly, the interaction of FLAG-LMP1
(T208A) with TRAF3 was similar to that of FLAG-LMP1
(WT). FLAG-LMP1(P204A) and FLAG-LMP1(T208A) inter-
acted very weakly with TRAF1, while FLAG-LMP1(PQ204/
206AA) and FLAG-LMP1(D204-208) were unable to interact
with TRAF1. As for FLAG-LMP1(WT), an interaction be-
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tween the LMP1 mutants and TRAF2 was not detected. Rep-
robing of the immunoblots with anti-LMP1 antibody indicated
that all LMP1 mutants were present at equal levels in the
immunoprecipitation reactions (a representative immunoblot
is shown in the lowest panel of Fig. 6A). These results indi-
cated that mutations in the LMP1 TRAF binding motif
PXQXT distinctly affect interaction with TRAF1 and TRAF3.
Since the interaction between LMP1 and endogenous
TRAF2 was not detectable, the abilities of the various FLAG-
LMP1 constructs to interact with overexpressed TRAF2 were
analyzed (Fig. 6B). When TRAF2 was overexpressed in C33A
cells, the interaction with FLAG-LMP1(WT) was readily de-
tectable. FLAG-LMP1(T208A) retained the ability to interact
weakly with TRAF2, while FLAG-LMP1(P204A) interaction
with TRAF2 was even weaker and was detectable only on
longer exposures of the TRAF2 immunoblot (Fig. 6B and data
not shown). FLAG-LMP1(PQ204/206AA) and FLAG-LMP1
(D204-208) did not interact with TRAF2. As described above,
reprobing of the immunoblots with anti-LMP1 antibody indi-
cated that all LMP1 mutants were present at equal levels in the
immunoprecipitation reactions (a representative immunoblot
is shown in the lowest panel of Fig. 6B). These results indicated
that TRAF2 can also interact with the PXQXT motif in
CTAR1 and that TRAF1, TRAF2, and TRAF3 each bind to
LMP1 in a unique manner. The interaction between FLAG-
LMP1 and the various point mutants with overexpressed
TRAF1 and TRAF3 was identical to that observed with en-
dogenous TRAF1 and TRAF3 (compare Fig. 6B and A). Anal-
ysis of the strength of binding between LMP1 and overex-
pressed TRAF proteins indicated that only 4% of total TRAF2
interacted with LMP1, while at least 25% of TRAF1 and 50%
of TRAF3 were bound to LMP1 (data not shown). The lack of
detectable interaction between LMP1 and endogenous
TRAF2 could therefore reflect the very weak interaction with
TRAF2 or could indicate that TRAF2 expression in C33A cells
is very low.
Interestingly, the interaction of TRAF3 with LMP1 specifi-
cally correlated with the ability of LMP1 to induce expression
of the EGFR (compare the uppermost panels in Fig. 4C and
6A). Mutants P204A, PQ204/206AA, and D204-208 were in-
creasingly more defective in EGFR induction (Fig. 4C) and in
TRAF3 binding (Fig. 6A), while the T208A mutation de-
creased binding of TRAF1 and TRAF2 but did not affect
TRAF3 binding or EGFR induction. However, LMP1(WT)
and LMP1(T208A), which both induced high levels of EGFR
expression, retained binding to TRAF1, -2, and -3, suggesting
that all three TRAF proteins contribute to EGFR induction.
Effect of overexpression of individual TRAF proteins on
EGFR induction. Previous reports have indicated that overex-
pressed TRAF2 acts as a positive regulator and overexpressed
TRAF3 acts as a negative regulator of TRAF-mediated acti-
vation of NF-kB (7, 8, 48, 57). To analyze the effects of these
molecules on the induction of EGFR expression, cell lines
overexpressing these proteins were established. The pMEP4
expression vector with the inducible metallothionein promoter
was used to establish a stable cell line overexpressing TRAF3
(pMEP4-TRAF3), in which TRAF3 expression could be fur-
ther induced with CdCl2 (Fig. 7A). pMEP4 and pMEP4-
TRAF3 cell lines were stably transfected with expression vec-
tors for CD40, or a combination of TRAF1 and TRAF2, and
the resulting cell lines were analyzed by immunoblotting for
induction of the EGFR (Fig. 7B, top). Expression of CD40 in
FIG. 6. In vivo analysis of TRAF binding to LMP1 proteins containing mu-
tations in the PXQXT TRAF binding domain. (A) C33A cells were transfected
with FLAG-LMP1 expression constructs containing mutations in the PXQXT
motif. (B) C33A cells were transfected with FLAG-LMP1 and TRAF expression
constructs. LMP1 was immunoprecipitated with anti-FLAG affinity gel, and
TRAF binding to each mutant was analyzed by immunoblotting. Immunoblots
were also reprobed with the anti-LMP1 monoclonal antibody S12 to ensure that
equal amounts of LMP1 were immunoprecipitated in all reactions.
FIG. 7. Effects of overexpression of individual TRAF proteins on EGFR
induction. (A) Establishment of a TRAF3-expressing cell line. pMEP4 or
pMEP4-TRAF3 was transfected into C33A cells, and following selection in
hygromycin, the cell lines were analyzed by immunoblotting for TRAF3 expres-
sion. The cell lines were either left untreated or treated with 50 mM CdCl2 for 6 h
to induce expression of the metallothionein-driven TRAF3 expression construct.
(B) TRAF1 and TRAF2 were stably overexpressed in the pMEP4 and pMEP4-
TRAF3 cell lines, and extracts were analyzed by immunoblotting. 1 and 2
indicate the pMEP4-TRAF3 and pMEP4 cell lines. The upper panel is an
immunoblot for EGFR expression, and the lower panels are immunoblots for
TRAF1 and TRAF2 expression. (C) The LMP1(WT), LMP1(1-231), or CD40
expression construct was transfected into either the pMEP4 or pMEP4-TRAF3
cell line. Resulting cell lines were analyzed by immunoblotting for EGFR ex-
pression (top) or TRAF3 expression (bottom). The immunoblot shown in the
upper left panel with FLAG-LMP1(WT) is a longer exposure reflecting the
somewhat weaker induction of EGFR expression by FLAG-LMP1(WT) than by
FLAG-LMP1(1-231) or CD40. Migration of molecular mass standards (in kilo-
daltons) is shown.
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the control pMEP4 cell line clearly resulted in the induction of
EGFR expression. Coexpression of TRAF1 and TRAF2 in the
control pMEP4 cell line did not induce EGFR expression,
although expression of TRAF2 activated the same NF-kB
complexes as CD40 (Fig. 2C). Expression of TRAF1 and
TRAF2 in these cell lines was confirmed by immunobloting
(Fig. 7B, lower two panels). Expression of TRAF1 or TRAF2
individually did not induce EGFR expression (data not
shown). Coexpression of TRAF1 and TRAF2 in the TRAF3-
overexpressing cell line also did not induce EGFR expression
(Fig. 7B, top). Therefore, overexpression of TRAF1, TRAF2,
and TRAF3 is unable to induce EGFR expression. These data
suggest that a proper complex of multiple TRAF proteins must
assemble at the plasma membrane with LMP1 or CD40 in
order to mediate EGFR induction.
To analyze the effect of TRAF3 overexpression on LMP1-
and CD40-mediated induction of EGFR expression, FLAG-
LMP1(WT), FLAG-LMP1(1-231), or CD40 was expressed in
either the pMEP4 or pMEP4-TRAF3 cell line (Fig. 7C). As
expected, expression of each of these proteins in the control
pMEP4 cell line resulted in the induction of EGFR expression
(Fig. 7C, top). In contrast, expression of FLAG-LMP1(WT) or
FLAG-LMP1(1-231) in the pMEP4-TRAF3 cell line de-
creased EGFR induction .90% compared to the pMEP4 con-
trol, while CD40-mediated EGFR induction was decreased
;75% (Fig. 7C, top). Analysis of TRAF3 expression in these
cell lines confirmed that TRAF3 was overexpressed in the
absence of CdCl2 (Fig. 7C, bottom). Increasing TRAF3 expres-
sion with CdCl2 did not further reduce EGFR expression (data
not shown). Since overexpression of TRAF3 decreased EGFR
induction mediated by LMP1, the effect of overexpression of
TRAF1 or TRAF2 was also analyzed in cell lines expressing
LMP1. In contrast to TRAF3, neither TRAF1 or TRAF2 af-
fected the induction of EGFR expression by LMP1 (data not
shown). These results indicate that overexpression of TRAF3
decreases induction of EGFR expression by either FLAG-
LMP1(WT), FLAG-LMP1(1-231), or CD40. Since TRAF3 has
the strongest binding capacity for LMP1 and because TRAF3
overexpression likely displaces other essential TRAFs, these
data suggest that induction of EGFR expression is dependent
on the appropriate stoichiometry of TRAF1, -2, and -3 with
LMP1 at the plasma membrane.
DISCUSSION
Of the two signaling domains in the LMP1 carboxy-terminal
cytoplasmic terminus, only CTAR1 is capable of inducing
EGFR expression (40). Both domains activate NF-kB, al-
though CTAR1 is a weaker activator (25% of the wild-type
level) in transient reporter gene assays compared to CTAR2
(75% of the wild-type level) (25, 40, 42). Since only CTAR1 is
capable of inducing EGFR expression, the specific NF-kB
components induced by CTAR1 and CTAR2 were analyzed.
The data presented here indicate that in C33A cells, CTAR1
activates a more diverse and robust nuclear mobilization of
NF-kB components as determined by EMSA (Fig. 2B).
LMP1(WT) induces three specific NF-kB complexes (com-
plexes 1, 2, and 3). LMP1(1-231), which retains CTAR1, in-
duces the same three complexes, while LMP1(D187-351),
which retains CTAR2, induces only complex 1. The data sug-
gest that in C33A cells, the difference in NF-kB activation
potential by CTAR1 and CTAR2 in transient reporter gene
assays may be reflected in the different repertoires of NF-kB
complexes induced by these domains. The relatively stronger
activation of NF-kB by CTAR2 in transient reporter gene
assays may result from activation of only complex 1 (p52-p65).
Complex 3 (p50-p50), which is induced strongly by CTAR1,
may dampen the NF-kB-activating effects of p52-p65 by com-
peting for kB sites in the reporter gene. This could effectively
lower the amount of CTAR1-mediated NF-kB activity in re-
porter gene assays without reflecting the effects of the individ-
ual NF-kB components on specific gene activation. It is possi-
ble that complex 2 (p50-p52), which is induced by CTAR1,
contributes to EGFR induction mediated by the TRAF do-
main. The NF-kB-regulated A20 gene is induced to equal
levels by either LMP1 signaling domain; therefore, activation
of complex 1 in C33A cells by mutants deleted in CTAR1, such
as like LMP1(D204-208) or LMP1(D187-351), is sufficient to
induce expression of A20. The data presented here indicate
that one of the distinct NF-kB complexes induced by CTAR1-
mediated TRAF signaling may contribute to high-level induc-
tion of EGFR expression.
Mutational analyses of the PXQXT motif in CTAR1 re-
vealed that the presence of these amino acids in LMP1 is
essential for induction of EGFR expression. Complete dele-
tion of the motif or substitution with alanines eliminated in-
duction of EGFR expression as well as the CTAR1-specific
NF-kB complexes. These experiments reveal that LMP1(D204-
208) is functionally identical to LMP1(D187-351). LMP1
(PQ204/206AA) induced low levels of complex 2 and reduced
levels of complex 3 compared to LMP1(WT) and also induced
low levels of EGFR expression. The induction of EGFR ex-
pression and activation of NF-kB complexes 2 and 3 by LMP1
in C33A cells are the first defined biochemical events that are
specific for TRAF activation through the TRAF-interacting
PXQXT motif.
These studies are also the first to analyze the effects of
mutations in the PXQXT motif on the ability of LMP1 to
interact with the TRAFs in vivo in comparison with EGFR
induction and NF-kB activation. LMP1(P204A) and LMP1
(PQ204/206AA) were reduced in the ability to induce EGFR
expression and the TRAF-specific NF-kB complexes. In con-
trast, LMP1(T208A) induced EGFR expression and activated
NF-kB comparably to LMP1(WT). Analysis of LMP1 interac-
tion with the TRAFs indicated that there was a close correla-
tion between EGFR induction and TRAF3 association with
LMP1. LMP1(P204A) and LMP1(PQ204/206AA) were re-
duced in the ability to interact with TRAF3 comparably with
their ability to induce EGFR expression. LMP1(T208A) asso-
ciated strongly with TRAF3 and induced EGFR expression
comparably to LMP1(WT). While interaction of LMP1 with
TRAF3 appears to directly correlate with EGFR induction,
TRAF2 and TRAF1 apparently contribute to high-level induc-
tion of EGFR expression. LMP1(T208A) still interacted
weakly with TRAF1 and TRAF2 and induced high levels of
EGFR expression, while LMP1(PQ204/206AA) was unable
to interact with TRAF1 and TRAF2 and induced low levels
of EGFR expression. These results suggest that interaction
of TRAF1, -2, and -3 with LMP1 contributes to induction of
EGFR expression. It is also possible that the interaction
of TRAF1 and TRAF2 with LMP1 contributes to high-level
EGFR induction through the activation of NF-kB. The activa-
tion of NF-kB and augmentation of EGFR induction by
TRAF1 and TRAF2 is also indicated by the finding that EGFR
induction was decreased in the presence of a constitutively
activate IkBa(SS32/36AA) molecule which behaves as an
NF-kB repressor.
Overexpression of TRAF2 in C33A cells either alone or in
combination with TRAF1 or TRAF3 does not induce EGFR
expression even though overexpression of TRAF2 resulted in
activation of the same three NF-kB complexes induced by
LMP1 and CD40. These results suggest that induction of
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EGFR expression requires clustering of the TRAFs through
the action of a membrane-bound receptor such as LMP1 or
CD40 and also that the activation of NF-kB complexes 2 and
3 by TRAF2 is insufficient to induce EGFR expression. The
interaction of LMP1 with TRAF3 appears to be required for
EGFR induction; however, interaction of TRAF3 with LMP1
is not the sole signaling molecule required for LMP1-mediated
EGFR induction, since overexpression of TRAF3 decreases
LMP1-mediated EGFR induction. Studies have shown that
overexpression of TRAF3 could displace more weakly inter-
acting TRAF molecules, which would effectively block the
LMP1 signal; thus, it is likely that TRAF3 overexpression dis-
places a TRAF which is also essential for EGFR induction (10,
51). These results indicate that activation of this signaling
pathway requires the correct assembly and stoichiometry of the
TRAF molecules with LMP1 at the cell membrane.
The involvement of TRAF3 in LMP1-mediated induction of
EGFR expression suggests that although TRAF2 appears to be
the major regulator of NF-kB activation, the other TRAFs also
mediate distinct TRAF signaling events. Interestingly, recent
studies with TRAF3-deficient mice suggest a positive role for
TRAF3 in TRAF signaling pathways (65). These mice become
increasingly runted with age, correlating with a depletion of
peripheral leukocytes and death by day 10. These results sug-
gest that TRAF3 may play a critical role in survival of B
precursor cells (65). The importance of TRAF3 in EGFR
induction also suggests that TRAF3 is a positive factor during
TRAF signaling events. TRAF3 is likely to be particularly
important for the growth-promoting effects of LMP1 on epi-
thelial cells, where EGFR expression is necessary for prolifer-
ation (39).
Although the PXQXT motif is the sole TRAF binding site in
LMP1, surrounding residues in LMP1 contribute to the
strength of interaction with the TRAFs (10). Specifically, GST-
LMP1(199-214) with the P204A mutation decreased TRAF1,
-2, and -3 binding by .99%, while GST-LMP1(187-231) or
FLAG-LMP1(1-231) with the P204A mutation demonstrated
strong binding to TRAF3, reduced binding to TRAF1, and
little or no binding to TRAF2 (10). In the context of full-length
LMP1(WT) proteins, the results presented here confirm the
previous observations and extend the analysis to include mu-
tations in other residues in the PXQXT motif. Particularly
interesting is the strength with which LMP1(T208A) binds to
the TRAFs. Full-length LMP1(T208A) retained TRAF3 bind-
ing comparably to LMP1(WT) and retained the ability to in-
teract with TRAF1 and TRAF2 (Fig. 6). The same mutation in
GST-LMP1(199-214) abrogated binding to TRAF1, -2, and -3
by greater then 95% (10). Comparison of functional LMP1
signaling with regard to EGFR induction also highlights the
differences between full-length LMP1 and LMP1(1-231).
While LMP1(1-231) mutated in either P204A or PQ204/
206AA is completely unable to induce EGFR expression, full-
length LMP1 proteins with these same mutations are still able
to induce intermediate to low levels of EGFR expression.
These results confirm the suggestion that amino acids sur-
rounding the PXQXT motif in LMP1 contribute to the
strength of interactions with the TRAFs and also enhance the
functional effects of signaling from CTAR1.
LMP1 has many of the same signaling properties as the
TNFR family members CD40 and CD30, which share the core
TRAF binding motif PXQXT (7, 10, 18, 24). In agreement
with this observation is the finding that CD40, like LMP1, can
interact with the TRAF molecules and induce expression of
the EGFR (8, 24, 40, 53). CD40 has been shown to interact
with TRAF2, -3, -5, and -6 (24, 26–28, 52). These studies
revealed that the T234A mutation in the PXQXT motif of
CD40 prevented interaction with TRAF2, -3, and -5 and pre-
vented CD40 signaling. The data presented in this study indi-
cate that the T234A mutant was completely deficient in EGFR
induction, although the analogous mutation in LMP1 did not
block EGFR induction. These results and the data for the
LMP1(1-231) mutants indicate that each amino acid in the
PXQXT motif, as well as surrounding residues, contributes to
TRAF interaction and reveals that the TRAFs interact differ-
ently with the CD40 and LMP1 TRAF domains. This is an
important difference and may facilitate the design of specific
inhibitors that could affect LMP1 signaling while leaving
TRAF signaling pathways from cellular proteins like CD30 and
CD40 largely unaffected.
Activation of TRAF signaling pathways by LMP1 is essential
for the immortalization of lymphocytes in vitro by EBV and
probably also in the establishment of epithelial malignancies
like NPC (30). Activation of NF-kB by LMP1 mediates impor-
tant aspects of the transformation process; however, pathways
other than NF-kB activated by the TRAF signaling pathway
are also likely to be important in mediating the transforming
effects of LMP1. Deletion of the PXQXT motif in LMP1
abolishes interaction with the TRAF proteins and prevents
transformation of lymphocytes in vitro although the mutated
LMP1 induces high levels of NF-kB (30). The data presented
in this study demonstrate that deletion of the PXQXT motif
prevents induction of EGFR expression in epithelial cells. The
recruitment of a proper combination of TRAF molecules to
CTAR1 in LMP1 results in the activation of signaling path-
ways, leading to activation of NF-kB and induction of mole-
cules like the EGFR. Recent studies indicate that induction of
E-selectin by the TRAF pathway involves activation of both
the c-Jun and NF-kB transcription factors (41). However,
these two essential pathways were both activated by TRAF2
(41). High-level EGFR induction by the TRAF pathway also
requires two signals; one requires activation of NF-kB through
LMP1-TRAF2 interaction, and the second is dependent on
assembly of an LMP1 complex containing TRAF1, -2, and -3.
The study of pathways activated by LMP1-TRAF interactions
is essential to further understand LMP1 function and is likely
to identify signaling pathways and downstream targets which
are critical to lymphoid and epithelial cell transformation.
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